Xubin Deng

Xubin Deng


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LMLei Ma
Lei Ma
YZYongjian Zhou
Yongjian Zhou
XLXiaojun Luo
Xiaojun Luo
HGHai Gao
Hai Gao
XDXubin Deng
Xubin Deng
YJYingjie Jiang
Yingjie Jiang
Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer

15 May 2014
Verified
Journal Article
Closed access
WLWeidong Li
Weidong Li
XJXuejun Jin
Xuejun Jin
QZQianbing Zhang
Qianbing Zhang
GZGong Zhang
Gong Zhang
XDXubin Deng
Xubin Deng
LMLei Ma
Lei Ma

15 July 2019 in Epigenomics
Verified
Journal Article
Closed access
YLYaoyong Lu
Yaoyong Lu
XDXubin Deng
Xubin Deng
GXGuanghui Xiao
Guanghui Xiao
XZXin Zheng
Xin Zheng
LMLei Ma
Lei Ma
WHWendong Huang
Wendong Huang
Aim: To study the role of circRNA (circ_0001730) in glioblastoma. Materials & methods: The interaction between circ_0001730 and miR-326 was confirmed by FISH, RNA pull down, RNA-binding protein immunoprecipitation and luciferase reporter assays. Cell proliferation and growth were determined by MTT, EdU and colony formation assays. Cell migration was assessed by the Boyden assay. Results: The levels of circ_0001730 were elevated in glioblastoma cell lines and tissues. circ_0001730 downregulation suppressed migration and proliferation in glioblastoma cells. SP1 bounds to the promoter of circ_0001730 host gene EPHB4 thereby increasing the expression of circ_0001730. circ_0001730 activated the Wnt/β-catenin pathway via the miR-326/Wnt7B axis. Conclusion: circ_000173 promoted growth and invasion in glioblastoma cells via the miR-326/Wnt7B axis.

15 February 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YLYaoyong Lu
Yaoyong Lu
YLYingying Liang
Yingying Liang
XZXin Zheng
Xin Zheng
XDXubin Deng
Xubin Deng
WHWendong Huang
Wendong Huang
GZGong Zhang
Gong Zhang
Aberrant EVI1 expression is frequently reported in cancer studies; however, its role in nasopharyngeal carcinoma (NPC) has not been examined in detail. The aim of the present study is to investigate the involvement of EVI1 in progression and prognosis of NPC. RT-PCR, immunohistochemistry and western blot assays were used to examine the expression of EVI1 in NPC tissues and cell lines. Fluorescence in situ hybridization assay was used to examine the amplification of EVI1 in NPC tissues. The biological effect of EVI1 was determined by both in vitro and in vivo studies. The dual-luciferase reporter assay was performed to confirm that EVI1 bind at E-cadherin andβ-catenin promoters. The ChIP, EMSA, and coimmunoprecipitation combined with mass spectrometry assays were used to analyze the EVI1 regulated proteins. EVI1 expression level was up-regulated in NPC tissues and cell lines. EVI1 was amplificated in NPC tissues. We observed that EVI1 down-regulation decreased the cell proliferation and invasive capacity of NPC cells in vitro and in vivo. EVI1, snail, and HDAC1 formed a co-repressor complex to repress E-cadherin expression and ultimately contributed to epithelial mesenchymal transition (EMT) phenotype in NPC cells. In another way, EVI1 directly bound at β-catenin promoter and activated its expression. β-catenin mediated EVI1’s function on cancer stem cells (CSCs) properties. EVI1 up-regulation predicted unfavorable prognosis and contributed to chemo/radio-resistance in NPC cells. Finally, we constructed arsenic trioxide-loaded nanoparticles (ALNPs) and revealed that ALNPs exerted anti-tumor effect in NPC cells. Our data indicated that EVI1 played an oncogenic role in NPC growth and metastasis and that EVI1 might serve as a novel molecular target for the treatment of NPC.

20 September 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYing Lu
Ying Lu
LLLing-Ling Liu
Ling-Ling Liu
SLShou-Sheng Liu
Shou-Sheng Liu
ZFZhi-Gang Fang
Zhi-Gang Fang
YZYong Zou
Yong Zou
DLDong-Jun Lin
Dong-Jun Lin
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder. Tyrosine kinase inhibitors (TKIs) are the standard treatments for CML, but a number of patients fail to respond effectively due to gene mutations. Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, has been shown to have anti-tumor effect on solid tumor whereas the anti-CML effect and its underlying mechanism have not been completely elucidated. The cytotoxic effects of celecoxib and/or imatinib were evaluated by MTT assay. Cell cycle distribution was examined by propidium iodide (PI) assay. Apoptosis or necrosis was analyzed by Annexin-V/PI, Hoechst 33342 staining and Western blot assays. Autophagy suppression effect of celecoxib was examined by Western blot and LysoTracker probe labelling. Lysosensor probe labelling was used to detect the effect of celecoxib on the lysosomal function. In this study, we found that celecoxib had therapy efficacy in KBM5 and imatinib-resistant KBM5-T315I CML cell lines. Celecoxib caused significant cytotoxic effect in both cell lines, especially in KBM5-T315I cells exposed to celecoxib for 72 h. Moreover, celecoxib induced necrosis and apoptosis while inhibited autophagy in CML cell lines and patient samples. Furthermore, this study demonstrated that celecoxib prevented the autophagic flux by inhibiting lysosome function. Celecoxib was tested in combination with imatinib, demonstrating that celecoxib could strengthen the cytotoxicity of imatinib in imatinib-resistant CML cells. These findings showed that celecoxib had therapy efficacy on CML cells. And it is first time to demonstrate that celecoxib is an autophagy suppresser and a combination of celecoxib and imatinib might be a promising new therapeutic strategy for imatinib-resistant CML cells.

11 April 2017 in Oncotarget
Verified
Journal Article
Open access
WLWeidong Li
Weidong Li
XMXiaobo Miao
Xiaobo Miao
LLLingling Liu
Lingling Liu
YZYue Zhang
Yue Zhang
XJXuejun Jin
Xuejun Jin
XDXubin Deng
Xubin Deng
Methylation-mediated silencing of microRNA-211 promotes cell growth and epithelial to mesenchymal transition through activation of the AKT/β-catenin pathway in GBM